Prelude Therapeutics to raise $100M in share sale

Prelude Therapeutics wills sell several million new shares of stock this month to raise $100 million in new capital to fund its drug pipeline studies. | PHOTO COURTESY OF NASDAQ WILMINGTON – Prelude Therapeutics, the clinical-stage precision oncology company, announced Thursday that it’s selling millions of new shares in the publicly

Already a subscriber? Log in

To continue reading this article ...

Subscribe to Delaware Business Times right now and get access to subscriber-only content like this article.

- Advertisement -

Plus get 24 issues of DBT via print or digital, special bonus issues, and discounted registration for our in-person events.

– Digital Partners -

Important information for subscribers accessing "Insider" content

Close the CTA